Table 2.
Gonadotropin and Sex Hormone Levels at Baseline and During Puberty Suppression Therapy
| Baseline |
Follow-upa |
|||||
|---|---|---|---|---|---|---|
| CPP | Transgender | p | CPP | Transgender | p | |
| Male/AMABb | ||||||
| LH (mIU/mL) | 2.9±1.6 | 1.8±1.4 | NS | 0.4±0.4 | 0.6±0.8 | NS |
| FSH (mIU/mL) | 8.0±9.1 | 2.9±1.9 | 0.03 | 0.4±0.2 | 0.5±0.3 | NS |
| Testosterone (ng/dL) | 180.8±112.7 | 282.3±224.7 | NS | 6.4±2.6 | 12.1±14.7 | NS |
| Female/AFABc | ||||||
| LH (mIU/mL) | 2.4±2.9 | 3.1±2.9 | NS | 0.4±0.4 | 0.3±0.2 | NS |
| FSH (mIU/mL | 4.8±3.1 | 3.8±2.3 | NS | 1.6±0.7 | 2.0±1.1 | NS |
| Estradiol (pg/mL) | 22.1±26.5 | 50.5±46.9 | 0.02 | 1.8±1.8 | 9.4±9.7 | 0.001 |
a
Time after onset of GnRH therapy: 5.2±1.9 months in the CPP group and 5.9±2.9 months in the transgender group, p=NS.
b
Males with CPP and AMAB transgender patients.
c
Females with CPP and AFAB transgender patients.
FSH, follicle-stimulating hormone; LH, luteinizing hormone.